Spanish experience of an extensively hydrolyzed formula with lactose and human milk oligosaccharides in cow's milk allergy.
4 affiliations
- 1Pediatrics Service, Amante Laffón Healthcare Centre, Seville, Spain.
- 2Pediatrics Service, Campanar Healthcare Center, Valencia, Spain.
- 3Medical Affairs Manager, Nestlé Health Science Spain, Barcelona, Spain. [email protected].
- 4Nestlé Health Science Spain, Carrer de Clara Campoamor, 2. 08950 - Esplugues de Llobregat, Barcelona, Spain. [email protected].
Abstract
Background
Despite the evidence supporting the efficacy of extensively hydrolyzed formulas (eHF) and human milk oligosaccharides (HMO) for the management of cow's milk protein allergy (CMPA), data on their use in clinical practice remain limited. The objective of the study was to describe the current landscape of CMPA management in Spanish primary care consultations, with particular emphasis on eHFs and novel immunomodulatory components (purified lactose or HMO).Methods
ELEVA was a multicenter, descriptive, ecological study involving 191 pediatricians with experience on CMPA management. Aggregated data derived from their experience on CMPA management.Results
The eHFs were the most commonly prescribed first-line option for mild and moderate CMPA (78.5% and 95.8%, respectively), while elemental formulas were mainly used in severe cases (61.8%). Infants who received an eHF supplemented with purified lactose and two HMO improved their digestive symptoms (77.4%), showed a reduction of crying and/or irritability symptoms (63.1%), normalization of stool consistency (51.6%), avoidance the rejection/difficulty for eating (48.2%), or a reduction of the number of stools (44.9%).Conclusions
The ELEVA study offers detailed insights into how pediatricians in Spain manage CMPA in clinical practice. It also highlights the integration of innovative tools, such as the CoMiSS™ awareness tool for CMPA diagnosis, and novel treatment components like purified lactose and HMO. The use of an eHF supplemented with purified lactose and HMO appears effective in alleviating digestive issues and irritability symptoms. Additionally, it may influence the incidence of infections, use of medication, and number of visits to the healthcare center.
Related
- Hydrolyzed Rice Formula for the Management of Cow’s Milk Allergy in Infants and Young Children: A Systematic Review of Randomized Controlled Trials
- Carcass Traits, Meat Quality, Hydrolyzed Amino Acid Composition, and GC-IMS Volatile Signal Profiles in Kazakh Lambs Fed Diets Containing Fermented Cottonseed Hulls.
- Polymorphism can extensively reshape the genome-wide crossover landscape in Arabidopsis thaliana
- Evaluation of Enzymatically Hydrolyzed Hermetia illucens Larval Homogenate as a Dietary Supplement for 1-21-Day-Old Broilers: Growth Performance, Meat Quality, Serum Biochemical Indices and Intestinal Morphology.
- Human-targeted drugs extensively reshape regulatory networks controlling virulence and antibiotic resistance in Salmonella Typhimurium
BibTeX
@article{coronelrodriguez2026spanish,
title = {{Spanish experience of an extensively hydrolyzed formula with lactose and human milk oligosaccharides in cow's milk allergy.}},
author = {Cristóbal Coronel-Rodríguez and Marta Castell Miñana and Miquel Layola Brias and participants from ELEVA study},
journal = {BMC primary care},
year = {2026},
month = jul,
doi = {10.1186/s12875-026-03481-5},
url = {https://europepmc.org/article/MED/42897459},
note = {CC BY},
}
RIS
TY - JOUR
TI - Spanish experience of an extensively hydrolyzed formula with lactose and human milk oligosaccharides in cow's milk allergy.
AU - Cristóbal Coronel-Rodríguez
AU - Marta Castell Miñana
AU - Miquel Layola Brias
AU - participants from ELEVA study
PY - 2026
DA - 2026/07/01
JO - BMC primary care
DO - 10.1186/s12875-026-03481-5
UR - https://europepmc.org/article/MED/42897459
AB - Background Despite the evidence supporting the efficacy of extensively hydrolyzed formulas (eHF) and human milk oligosaccharides (HMO) for the management of cow's milk protein allergy (CMPA), data on their use in clinical practice remain limited. The objective of the study was to describe the current landscape of CMPA management in Spanish primary care consultations, with particular emphasis on eHFs and novel immunomodulatory components (purified lactose or HMO).Methods ELEVA was a multicenter, descriptive, ecological study involving 191 pediatricians with experience on CMPA management. Aggregated data derived from their experience on CMPA management.Results The eHFs were the most commonly prescribed first-line option for mild and moderate CMPA (78.5% and 95.8%, respectively), while elemental formulas were mainly used in severe cases (61.8%). Infants who received an eHF supplemented with purified lactose and two HMO improved their digestive symptoms (77.4%), showed a reduction of crying and/or irritability symptoms (63.1%), normalization of stool consistency (51.6%), avoidance the rejection/difficulty for eating (48.2%), or a reduction of the number of stools (44.9%).Conclusions The ELEVA study offers detailed insights into how pediatricians in Spain manage CMPA in clinical practice. It also highlights the integration of innovative tools, such as the CoMiSS™ awareness tool for CMPA diagnosis, and novel treatment components like purified lactose and HMO. The use of an eHF supplemented with purified lactose and HMO appears effective in alleviating digestive issues and irritability symptoms. Additionally, it may influence the incidence of infections, use of medication, and number of visits to the healthcare center.
SN - 2731-4553
ER -